Amgen Inc. (NASDAQ:AMGN) Receives $354.17 Average Price Target from Analysts

Amgen Inc. (NASDAQ:AMGN) has received an average rating of “Hold” from the thirty research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $354.00.

AMGN has been the topic of a number of research analyst reports. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Truist Financial lifted their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft increased their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. BMO Capital Markets lifted their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Prominent market commentator Josh Brown argued that large-cap biotech names are resilient to disruption, which supports investor appetite for Amgen as a stable growth biotech. Josh Brown: Biotech growth stocks immune to disruption risk
• Positive Sentiment: Analysis highlighting Amgen’s oncology advances and a resilient dividend argues the company’s product progress and cash generation underpin long‑term growth, a supportive signal for income and growth investors. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Neutral Sentiment: Seeking Alpha published the transcript of Amgen’s presentation at the Leerink Global Healthcare Conference — useful for pipeline, management commentary and strategic color, but no single market-moving announcement in the transcript. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: A valuation piece assesses whether AMGN shares are mispriced after mixed returns — useful background for longer‑term positioning but not an immediate catalyst. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest reports in the feed show anomalous/zero values and contradictory entries for March — current data appears unreliable and is not a usable signal for positioning right now.
• Negative Sentiment: Jefferies initiated coverage on Amgen with a Hold and set a $350 price target, below the current market price — this analyst call introduces near‑term downside pressure and may weigh on sentiment. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: New federal legislation (H.R. 7871) that would formalize value‑based purchasing in Medicaid and change price/rebate calculations could create pricing/reporting pressures for manufacturers, introducing regulatory risk for Amgen’s marketed drugs. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

Amgen Price Performance

Shares of AMGN opened at $377.64 on Friday. Amgen has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market cap of $203.57 billion, a PE ratio of 26.54, a P/E/G ratio of 3.72 and a beta of 0.45. The firm has a 50-day simple moving average of $356.15 and a two-hundred day simple moving average of $324.33. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is 70.84%.

Institutional Investors Weigh In On Amgen

A number of hedge funds have recently added to or reduced their stakes in the business. Meadowbrook Advisors Group LLC acquired a new position in shares of Amgen in the fourth quarter worth $2,100,000. Advisortrust Partners LLC purchased a new position in Amgen in the fourth quarter valued at $3,646,000. Corient Private Wealth LLC grew its stake in Amgen by 54.0% during the 4th quarter. Corient Private Wealth LLC now owns 537,630 shares of the medical research company’s stock worth $176,000,000 after purchasing an additional 188,531 shares in the last quarter. Union Savings Bank acquired a new position in Amgen during the 4th quarter worth $418,000. Finally, Hsbc Holdings PLC increased its holdings in Amgen by 7.7% during the 4th quarter. Hsbc Holdings PLC now owns 1,537,251 shares of the medical research company’s stock worth $503,570,000 after purchasing an additional 110,357 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.